Competition

Corporate / M&A

Employment and Executive Compensation

Healthcare / Life Sciences

IP / IT

Real Estate

Regulatory

Homburger for Biotronik

Homburger News

20250311_Biotronik

Homburger advises BIOTRONIK on sale of VI Business to Teleflex

On February 27, 2025, BIOTRONIK Group announced that it has entered into an agreement to divest its Vascular Intervention (VI) business division to Teleflex Incorporated. The transaction is subject to regulatory approvals and other customary closing conditions and is expected to close before the end of the third quarter of 2025.
BIOTRONIK is a Berlin-based global leader in medical technology and a pioneer in cardiovascular, endovascular, and neuromodulation solutions. Teleflex (NYSE: TFX) is a Pennsylvania-based leading global provider of medical technologies with a diverse portfolio, including solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care.
Homburger acts as Swiss transaction counsel to BIOTRONIK. The team includes Andreas Müller, Anna Peter, Jasmin Künzle, Romain Hondius, Oliver Kneubühl and Cédric Berger (all Corporate / M&amp;A), Richard Stäuber and Angelika Murer (both Regulatory), Luca Dal Molin and Philippe Baumann (both IP / IT), Stefan Gäumann (Real Estate), Jeremy Reichlin and Angela Casey (both Employment and Executive Compensation), as well as Reto Heuberger and Philippe Weber (both Tax).

Windward Bio_we_640x140

Share-Image Teamplate Deals-and-Cases

On January 10, 2025, Windward Bio Group AG, a Swiss-based private, clinical-stage, drug development company committed to improving outcomes for people living with advanced immunological diseases, announced its launch with a USD 200 m series A financing from lead investors OrbiMed, Novo Holdings and Blue Owl Healthcare Opportunities, and co-investors SR One, Omega Funds, RTW Investments, Qiming Venture Partners, Quan Capital and Pivotal bioVenture Partners. Windward Bio has entered into an agreement to license WIN378, a potential best-in-class, long-acting monoclonal antibody targeting the ligand of thymic stromal lymphopoietin (TSLP), from Kelun-Biotech and Harbour BioMed for global rights, excepting China and select smaller markets in Asia.
Proceeds from the financing will be used to develop a phase 2-ready, long-acting anti-TSLP antibody with best-in-class potential in asthma and chronic obstructive pulmonary disease (COPD).
Homburger AG advises Windward Bio on its set-up and financing. The Homburger team comprises Andreas Müller, Margrit Marti, Oliver Kneubühl, Kaiyan Yeo, Eric Huber, Jonas Stähli, Rebecca Sigrist and Carolina Rodriguez (all Corporate / M&amp;A), Stefan Oesterhelt and Juliette Buob (both Tax) and Luca Dal Molin (IP / IT).

Homburger advises Windward Bio on its USD 200 m Series A Financing

Capital Markets

Financing and Investment Products

YODA plc_web_640x140

On December 27, 2024, Yoda PLC, a Cyprus-based investment corporation listed on the Cyprus stock exchange (CSE: YODA), announced the completion of its major investment into ULTIMA CAPITAL SA (Ultima), a Swiss luxury real estate owner, developer and operator listed on BX Swiss (BX: ULTIMA).
As part of the transaction, Yoda has transferred to Ultima, by way of a contribution in kind, 100% of the issued share capital of its wholly-owned subsidiary Papacamp Investments Limited (Papacamp) at a contribution value of approximately CHF 484.6 m in return for 8,076,667 newly-issued shares of Ultima. Papacamp indirectly owns real estate properties and real estate developments in Greece within the luxury hospitality sector. As a result of the transaction, Yoda has become Ultima&#8217;s largest shareholder, with a shareholding interest in Ultima of approximately 53.8%. In addition, Yoda has granted Ultima a loan in the amount of CHF 71 m.
The Homburger team advising Yoda on all aspects of the transaction was led by Stefan Blunschi and included Micha Fankhauser, Oliver Kneubühl, Jonas Stähli and Leander Etter (all Corporate / M&amp;A), Lorenzo Togni and Kaiyan Yeo (both Capital Markets), Claudia Suter, Philippe Weber and Philippe Gobet (all Tax), Stefan Bindschedler and Nathalie Scherrer (both Financing and Investment Products), Stefan Gäumann and Olivier Bühlmann (both Real Estate), and Richard Stäuber and David Thomann (both Regulatory).

Oliver
Kneubühl

Homburger advises BIOTRONIK on sale of VI Business to Teleflex

Homburger advises Windward Bio on its USD 200 m Series A Financing

Homburger advised Yoda PLC on its investment into ULTIMA CAPITAL SA

Haftungsrechtliche Folgen einer gesetzlichen Regelung der Ad hoc-Publizität

Swissair: Pflichtgemässe Verletzung von Kapitalschutzvorschriften?

Join the Team

Oliver Kneubühl

Career

Languages

Bar Registration

Teams

OliverKneubühl

Homburger advises BIOTRONIK on sale of VI Business to Teleflex

Homburger advises Windward Bio on its USD 200 m Series A Financing

Homburger advised Yoda PLC on its investment into ULTIMA CAPITAL SA

Haftungsrechtliche Folgen einer gesetzlichen Regelung der Ad hoc-Publizität

Swissair: Pflichtgemässe Verletzung von Kapitalschutzvorschriften?

Join the Team

Oliver Kneubühl

Career

Languages

Bar Registration

Teams

Oliver
Kneubühl